Multicenter double-blind study of moclobemide and maprotiline

Area of Science:

• Psychiatry
• Pharmacology

Background:

• Depression is a prevalent mental health disorder requiring effective pharmacological interventions.
• Selective and reversible monoamine oxidase-A inhibitors offer a potential therapeutic avenue for depression.

Purpose of the Study:

• To compare the efficacy and tolerability of moclobemide, a selective reversible monoamine oxidase-A inhibitor, against maprotiline in depressed patients.
• To assess the speed of onset and adverse event profiles of both antidepressant medications.

Main Methods:

• A 6-week, randomized, double-blind, multicenter study involving 80 depressed patients.
• Patients received either moclobemide (300 mg daily) or maprotiline (75 mg daily).
• Efficacy was measured using the Hamilton Depression Rating Scale (HDRS) and Clinical Global Impression (CGI); tolerability was assessed via adverse event reports.

Main Results:

• Both moclobemide and maprotiline groups showed significant improvements in HDRS and CGI scores after 6 weeks.
• Moclobemide exhibited a significantly faster onset of action, with differences noted by week 3 (p = 0.025).
• Moclobemide was associated with significantly fewer adverse events (28.9% vs. 70.2%), including less weight gain and fewer anticholinergic side effects.

Conclusions:

• Moclobemide and maprotiline are therapeutically equivalent in treating major depressive disorder, neurotic depression, and adjustment-prolonged depressive reactions.
• Moclobemide offers a better tolerability profile and a faster onset of antidepressant action compared to maprotiline.
• The findings support moclobemide as a well-tolerated and effective option for depression management.